Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent listeria monocytogenes-based vaccines

Journal of Immunotherapy

Volumn 32, Issue 8, 2009, Pages 856-869

  Sinnathamby, Gomathinayagam ^a   Lauer, Peter ^b   Zerfass, Jennifer ^a   Hanson, Bill ^b   Karabudak, Aykan ^a   Krakover, Jonathan ^a   Secord, Angeles Alvarez ^c   Clay, Timothy M ^c   Morse, Michael A ^c   Dubensky Jr , Thomas W ^b   Brockstedt, Dirk G ^b   Philip, Ramila ^a   Giedlin, Martin ^b,d  

^a Immunotope Inc   (United States)

^b Anza Therapeutics Inc   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d SANGAMO BIOSCIENCES INC   (United States)

Author keywords

CD8+ T cell epitopes; Immune responses; Ovarian and breast cancers; Recombinant Listeria monocytogenes

Indexed keywords

BACTERIAL VACCINE; EPITOPE; LIVE VACCINE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LISTERIA MONOCYTOGENES; MASS SPECTROMETRY; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLONING, MOLECULAR; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A2 ANTIGEN; HUMANS; LISTERIA INFECTIONS; LISTERIA MONOCYTOGENES; LYMPHOCYTE ACTIVATION; MONOCYTES; OVARIAN NEOPLASMS;

EID: 70349673721     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181b0b125     Document Type: Article

References (30)

1. Nijman HW, van Diest PJ, Poort-Keesom RJ, et al. T cell infiltration and MHC I and II expression in the presence of tumor antigens: an immunohistochemical study in patients with serous epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2001;94:114-120.
2. Hwu P, Freedman RS. The immunotherapy of patients with ovarian cancer. J Immunother. 2002;25:189-201.
3. S3. Ho O, Green WR. Alternative translational products and cryptic T cell epitopes: expecting the unexpected. J Immunol. 2006;177:8283-8289.
4. Ho O, Green WR. Cytolytic CD8+ T cells directed against a cryptic epitope derived from a retroviral alternative reading frame confer disease protection. J Immunol. 2006;176: 2470-2475.
5. Weinzierl AO, Maurer D, Altenberend F, et al. A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays. Cancer Res. 2008;68:2447-2454.
6. Skipper JC, Gulden PH, Hendrickson RC, et al. Massspectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer. 1999;82:669-677.
7. Ramakrishna V, Ross MM, Petersson M, et al. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol. 2003;15: 751-763.
8. Bruhn KW, Craft N, Miller JF. Listeria as a vaccine vector. Microbes Infect. 2007;9:1226-1235.
9. Bahjat KS, Prell RA, Allen HE, et al. Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease. J Immunol. 2007;179:7376-7384.
10. Cousens LP, Wing EJ. Innate defenses in the liver during Listeria infection. Immunol Rev. 2000;174:150-159.
11. Portnoy DA. Innate immunity to a facultative intracellular bacterial pathogen. Curr Opin Immunol. 1992;4:20-24.
12. Brockstedt DG, Giedlin MA, Leong ML, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci USA. 2004;101:13832-13837.
13. Weiskirch LM, Paterson Y. Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease. Immunol Rev. 1997;158:159-169.
14. O'Riordan M, Yi CH, Gonzales R, et al. Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc Natl Acad Sci USA. 2002;99:13861-13866.
15. Serbina NV, Kuziel W, Flavell R, et al. Sequential MyD88- independent and -dependent activation of innate immune responses to intracellular bacterial infection. Immunity. 2003; 19:891-901.
16. Serbina NV, Salazar-Mather TP, Biron CA, et al. TNF/iNOSproducing dendritic cells mediate innate immune defense against bacterial infection. Immunity. 2003;19:59-70.
17. Lauer P, Chow MY, Loessner MJ, et al. Construction, characterization, and use of two Listeria monocytogenes sitespecific phage integration vectors. J Bacteriol. 2002;184: 4177-4186.
18. Brockstedt DG, Bahjat KS, Giedlin MA, et al. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med. 2005;11:853-860.
19. Jerome KR, Domenech N, Finn OJ. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol. 1993;151:1654-1662.
20. Yoshino I, Goedegebuure PS, Peoples GE, et al. HER2/neuderived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res. 1994;54: 3387-3390.
21. Yoshino I, Peoples GE, Goedegebuure PS, et al. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol. 1994;152:2393-2400.
22. Babcock B, Anderson BW, Papayannopoulos I, et al. Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex. Mol Immunol. 1998;35:1121-1133.
23. Grossmann ME, Davila E, Celis E. Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother. 2001;24:237-241.
24. Makki A, Weidt G, Blachere NE, et al. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor. Cancer Immun. 2002;2:4.
25. Slifka MK, Blattman JN, Sourdive DJ, et al. Preferential escape of subdominant CD8+ T cells during negative selection results in an altered antiviral T cell hierarchy. J Immunol. 2003;170: 1231-1239.
26. Sykulev Y, Joo M, Vturina I, et al. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity. 1996;4:565-571.
27. Lauer P, Hanson B, Lemmens EE, et al. Constitutive activation of the PrfA regulon enhances the potency of vaccines based on live-attenuated and killed but metabolically active Listeria monocytogenes strains. Infect Immun. 2008; 76:3742-3753.
28. Bouwer HG, Shen H, Fan X, et al. Existing antilisterial immunity does not inhibit the development of a Listeria monocytogenes-specific primary cytotoxic T-lymphocyte response. Infect Immun. 1999;67:253-258.
29. Popov A, Driesen J, Abdullah Z, et al. Infection of myeloid dendritic cells with Listeria monocytogenes leads to the suppression of T cell function by multiple inhibitory mechanisms. J Immunol. 2008;181:4976-4988.
30. Skoberne M, Yewdall A, Bahjat KS, et al. KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. J Clin Invest. 2008;118:3990-4001.